Firstly, while genetic knockout models could provide deeper mechanistic insights, our experimental design prioritized pharmacological interventions with PT2385—a clinically validated HIF2α inhibitor currently in phase II trials for renal carcinoma. This evidence concerns the gene EPAS1 and renal carcinoma.